

# Machine Preservation Trial

MP vs. CS in Kidney Transplantation in collaboration with Eurotransplant



---

## Scientific Steering Committee

### Principal Investigators



Rutger J. Ploeg (Coord.)



Jacques Pirenne



Andreas Paul

### Members

Cyril Moers (Secretary)

Hugo Maathuis (RPC Liaison)

Jaap Homan v/d Heide

Ernst van Heurn

Frank van Gelder

Jean-Paul Squifflet

Jürgen Treckmann

Massimo Malago

---

## Central Trial Assistance

### Eurotransplant

Bernard Cohen

Jacqueline Smits

Margitta van Kasterop-Kutz

### Deutsche Stiftung

#### Organtransplantation

Günter Kirste

Heiner Smit

---

## Regional Perfusion Centers

### Groningen, The Netherlands

Henri Leuvenink

### Leuven, Belgium

Frank van Gelder

### Essen, Germany

Bogdan Napieralski

---

## Sponsor

Organ Recovery Systems

## Protocol Amendment # 003

**Proposed by:** *RPC Groningen* **Date:** 15-03-2005

**Title:** *Viability assessment of donor kidneys undergoing hypothermic machine perfusion preservation*

### Background and Aim

*Machine perfusion (MP) may not only be a superior preservation method for marginal kidneys. It also offers the unique opportunity to assess isolated donor organs prior to transplantation, thus being a possible diagnostic tool for the transplant surgeon. So far, however, there is no scientific consensus about which parameters and markers are relevant for the assessment of machine perfused donor kidneys. The aim of this amendment is to measure several perfusate parameters known to be possibly related to organ quality and correlate them with new biomarkers and clinical follow-up data, to allow so the development of a clinically relevant and practical kit of MP viability assessment markers for future use in clinical routine.*

### Method

*From each MP procedure, perfusate samples will be taken at 0 and 1 hours after the start of perfusion. Another perfusate sample will be taken at the end of the MP procedure. Each sample will contain 10 ml of perfusate and will be taken by the perfusionist to be stored on ice. Perfusate samples will be collected and transported to the respective RPC and stored at  $-80^{\circ}\text{C}$ . Samples will be collected at regular intervals and analyzed at the end of the trial at the Groningen RPC.*

*Analysis will consist of:*

- *LDH*
- *lactate*
- *von Willebrand factor*
- *alanine-aminopeptidase*
- *alpha-GST*

### Statistics

*All measured parameters will be correlated to organ quality assessment by the transplant surgeon, donor and recipient demographics, perfusion pressure/flow read-out, post-transplant function, patient and graft survival, and acute rejection using a MVA.*